Cervical spondylotic myelopathy
Conditions
Interventions
Liposomal bupivacaine group:20 mL of liposomal bupivacaine (containing 266 mg of bupivacaine) was diluted with 20 mL of normal saline to a total volume of 40 ml, with 20 mL injected on each side of th
Ropivacaine group:20 mL of 0.5% ropivacaine, diluted with 20 mL of normal saline to a total volume of 40 ml, with 20 mL injected on each side of the incision
Sponsors
Lianyungang First People's Hospital
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 35 years old, gender not limited; 2. Diagnosed with cervical spondylotic myelopathy, and meets the surgical indications for posterior cervical single-door approach; 3. ASA classification (Grade I/II); 4. No cognitive impairment or other mental disorders.
Exclusion criteria
Exclusion criteria: 1. Allergic to the local anesthetic drugs used in the study; 2. Poor compliance and unable to complete the Visual Analogue Scale (VAS) for pain assessment; 3. Recent history of opioid drug use; 4. Severe liver and kidney dysfunction; 5. Participated in other clinical trials within 4 weeks prior to the surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative opioid consumption within 3 days post operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rescue analgesia requirement;Compressions of the analgesic pum;Time to first opioid use;Analgesia satisfaction scores within 3 days post operation;Visual analogue scale (VAS) scores;Adverse reactions post operation; | — |
Countries
China
Contacts
Public ContactYongtao Yang
Lianyungang First People's Hospital
Outcome results
None listed